Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action

被引：41

作者：

Olson, RE ^{[1
]}

Sielecki, TM ^{[1
]}

Wityak, J ^{[1
]}

Pinto, DJ ^{[1
]}

Batt, DG ^{[1
]}

Frietze, WE ^{[1
]}

Liu, J ^{[1
]}

Tobin, AE ^{[1
]}

Orwat, MJ ^{[1
]}

Di Meo, SV ^{[1
]}

Houghton, GC ^{[1
]}

Lalka, GK ^{[1
]}

Mousa, SA ^{[1
]}

Racanelli, AL ^{[1
]}

Hausner, EA ^{[1
]}

Kapil, RP ^{[1
]}

Rabel, HR ^{[1
]}

Thoolen, MJ ^{[1
]}

Reilly, TM ^{[1
]}

Anderson, PS ^{[1
]}

Wexler, RR ^{[1
]}

机构：

[1] Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 1999年 / 42卷 / 07期

关键词：

D O I：

10.1021/jm980348t

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Modification of the cc-carbamate substituent of isoxazoline GPIIb/IIIa (alpha(IIb)beta(3)) antagonist DMP 754 (7) led to a series of alpha-sulfonamide and alpha-sulfamide diaminopropionate isoxazolinylacetamides which were found to be potent inhibitors of in vitro platelet aggregation. Aryl- and heteroaryl-alpha-sulfonamide groups, in conjunction with (5R)-isoxazoline (2S)-diaminopropionate stereochemistry, were found to impart a pronounced duration of antiplatelet effect in dogs, potentially due to high affinity for unactivated platelets. Isoxazolylsulfonamide 34b (DMP 802), a highly selective GPIIb/IIIa antagonist, demonstrated a prolonged duration of action after iv and po dosing and high-affinity for resting and activated platelets. The prolonged antiplatelet profile of DMP 802 in dogs and the high affinity of DMP 802 for human platelets may be predictive of clinical utility as a once-daily antiplatelet agent.

引用

页码：1178 / 1192

页数：15

共 50 条

[1] ABRAMS C, 1997, ADV MOL CEL, V18, P67
[2] Non-peptide glycoprotein IIb/IIIa inhibitors .17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists
Askew, BC
Bednar, RA
Bednar, B
Claremon, DA
Cook, JJ
McIntyre, CJ
Hunt, CA
Gould, RJ
Lynch, RJ
Lynch, JJ
Gaul, SL
Stranieri, MT
Sitko, GR
Holahan, MA
Glass, JD
Hamill, T
Gorham, LM
Prueksaritanont, T
Baldwin, JJ
Hartman, GD
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) : 1779 - 1788
[3] Preparation and properties of some N-substituted sulfamic acids
Audrieth, LF
Sveda, M
[J]. JOURNAL OF ORGANIC CHEMISTRY, 1944, 9 (01) : 89 - 101
[4] Bednar B, 1997, CYTOMETRY, V28, P58, DOI 10.1002/(SICI)1097-0320(19970501)28:1<58::AID-CYTO7>3.0.CO
[5] 2-D
[6] Bednar RA, 1996, CIRCULATION, V94, P568
[7] ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS - RELATIONSHIP BETWEEN PHARMACODYNAMICS AND PHARMACOKINETICS
BELZ, GG
KIRCH, W
KLEINBLOESEM, CH
[J]. CLINICAL PHARMACOKINETICS, 1988, 15 (05) : 295 - 318
[8] Nonpeptide glycoprotein IIB/IIIA inhibitors .18. Indole alpha-sulfonamide acids are potent inhibitors of platelet aggregation
Brashear, KM
Cook, JJ
Bednar, B
Bednar, RA
Gould, RJ
Halczenko, W
Holahan, MA
Lynch, RJ
Hartman, GD
Hutchinson, JH
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (21) : 2793 - 2798
[9] Cannon CP, 1998, CIRCULATION, V97, P340
[10] RELATIONSHIPS BETWEEN CSF DRUG CONCENTRATIONS, RECEPTOR-BINDING CHARACTERISTICS, AND PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF SELECTED 1,4-SUBSTITUTED BENZODIAZEPINES
COLBURN, WA
JACK, ML
[J]. CLINICAL PHARMACOKINETICS, 1987, 13 (03) : 179 - 190

← 1 2 3 4 5 →